Adult T-cell leukemia/lymphoma (ATL) was first described as a new disease having unique clinicohematological, morphological, immunophenotypic, and epidemiological features (1) . Since 1981, it has been reported that nearly 100% of all patients with ATL have sera that react with the proteins of human T-cell leukemia virus type I (HTLV-I) (2) (3) (4) (5) (6) . In 1983, however, Shimoyama et al. (7) found that a few patients with ATL have typical clinicohematological, morphological, and immunophenotypic features but give a negative reaction for antibody to HTLV-I. Expression of HTLV-I protein in primary cultures of leukemia cells from those patients was also found to be negative (7) . Family members of the patients showing no anti-HTLV-I antibody were also negative for anti-HTLV-I antibody (7) . These results suggested that HTLV-I may not be involved in leukemogenesis in some patients with ATL. To determine whether HTLV-I is associated with leukemogenesis in these ATL patients, we examined the DNA of their leukemia cells by Southern blot analysis using probes of the HTLV-I proviral genome. No integration of the HTLV-I proviral genome into cellular DNA of leukemia cells could be detected in these patients who lack anti-HTLV-I antibody, suggesting that factor(s) other than HTLV-I may be involved in ATL leukemogenesis.
MATERIALS AND METHODS Surface Markers. Surface markers of leukemia cells were analyzed by use of a panel of 20 well-characterized monoclonal antibodies, described previously (8) . The markers examined were OKT3, Leu-4, OKT4, Leu-3a, OKT8, Leu2a, OKT6, NA1/34, OKT11, 9.6, Leu-5, Leu-1, 10.2, 4A, Ta6Ob (for interleukin-2 receptor), OKIal, HLA-DR, B1, J5, and BA-3. The leukemia cells were also cultured in the presence of crude T-cell growth factor (9) for induction of HTLV-I antigen in vitro. The expression of HTLV-I antigen in cultured leukemia cells was examined with reference sera that had high titers of anti-HTLV-I antibody and with two monoclonal antibodies (GIN-2 and GIN-14) against P19 and P28 (10).
Southern Blot Analysis. Mononuclear cells were prepared from fresh peripheral blood, ascites, or pericardial effusions of the patients, at the indicated clinical stages described under case reports, by centrifugation on a Ficoll-Conray gradient. For preparation of DNA for various blotting analyses, more than 107 lymphoid cells were used. High molecular weight DNA was extracted by treating the cells overnight with NaDodSO4/proteinase K and then extracting the mixture with phenol. Cellular DNA was digested with EcoRI, Pst I, or Msp I, and the fragments were separated by electrophoresis in 10% agarose gel. The DNAs in the gel were blotted onto a nitrocellulose membrane filter or nylon membrane filter and hybridized with nick-translated 32P-labeled probes. The probes used were pCAT-G [corresponding to nucleotides 874-2515 in the proviral genome (11) ], covering the gag region; pATK32 (nucleotides 1930-5093), covering the gag-pol region (11); pHT-I(M)3.9 (nucleotides 4990-8309), covering the env-pX region (12) ; and pHT-I(M)0.7 (nucleotides 8323-9003), covering the long terminal repeat (LTR) region (12) of cloned HTLV-I provirus (Fig. 1) . Plasmid pATK32 was kindly supplied by M. Yoshida (Cancer Institute, Tokyo). pHT-I(M)3.9, pHT-I(M)0.7, and pCAT-G were isolated in our laboratory. Hybridization was in 6x standard saline citrate (SSC)/5x Denhardt's solution/0.1% NaDodSO4/5 mM EDTA/Escherichia coli DNA (100 ,g/ml)/ yeast RNA (40,g/ml) for 48 hr at 65°C. The filter was washed twice for 15 min at room temperature and once for 30 min at 550C with 0.5x SSC/0.1% NaDodSO4 and then exposed to x-ray film at -700C. In another experiment, the filter was heated for 10 min at 95°C and rehybridized with nicktranslated c-myc. (lx SSC is 0.15 M NaCl/15 mM sodium citrate, pH 7.0; lx Denhardt's solution is 0.02% Ficoll/ 0.02% polyvinylpyrrolidone/0.02% bovine serum albumin.)
Patients. Between October 1980 and the end of 1984, sera of69 ATL patients were examined for anti-HTLV-I antibody. Seven of these sera were found to give a negative reaction for the antibody. Five of these seven cases could be used further for DNA analysis because enough tumor cells had been kept frozen. First, as it is important to show that these five ATL patients giving negative reaction for anti-HTLV-I antibody Abbreviations: ATL, adult T-cell leukemia/lymphoma; HTLV-I, human T-cell leukemia virus type I; LDH, lactate dehydrogenase; LTR, long terminal repeat; PBMC, peripheral blood mononuclear cell; kb, kilobase(s).
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. (Fig. 2d) . Mononuclear cells were separated from the ascites and stored at -80'C for HTLV-I proviral analysis (Fig. 3A) . Biopsy specimens of the gastric tumor disclosed lymphomatous infiltration. A few large abnormal lymphocytes with flower-cell morphology were seen in a peripheral blood smear. From these findings, a diagnosis of a lymphoma type of ATL was made (13 (Fig. 2e) , a high LDH level (1622 units/dl) and sarcomatous meningitis. Mononuclear cells were separated from the peripheral blood and stored at -800C for analysis of HTLV-I provirus (Fig. 3A) . Histological examination of the right inguinal lymph node revealed malignant lymphoma of diffuse pleomorphic cell type. He was diagnosed as having ATL. His condition deteriorated abruptly on July 18, and he died of acute heart failure.
RESULTS
Anti-HTLV-I Antibody in Sera and HTLV-I Protein in Cells. Sera were obtained before therapy and several times after the start of therapy. The sera were diluted 1:5 and screer'ed for anti-HTLV-I antibody by the indirect immuriofluorescence method (2) . In all five patients, negative results were consistently obtained. Moreover, no reactivity against HTLV-I antigens was detected in undiluted sera from any of the five patients. No antibody was detected in sera obtained from nine members of two families (patients 2 and 4), including the mother of one patient. In addition, expression of HTLV-I antigen was examined by the indirect immunofluorescence method in primary leukemia cells from the five patients, cultured in the presence of crude T-cell growth factor (9), but in all cases negative results were obtained.
Immunological Phenotype of Tumor Cells. As shown in Table 1 , leukemia cells from patients 2, 3, and 4 gave positive reactions for OKT3 or Leu-4, OKT4 or Leu-3a, OKT11 or 9.6, Leu-1 or 10.2, and OKIal or HLA-DR, but negative reactions for OKT8 or Leu-2a, indicating that the leukemia cells expressed the activated inducer/helper T-cell phenotype. Leukemia cells from two of these patients (nos. 2 and 3) were reexamined at the time of relapse. In patient 2, the immunological phenotype of leukemia cells at this time was the same as that before therapy. However, the leukemia cells of patient 3 at the time of relapse had gained reactivity with Leu 2a and become double-labeled cells (Leu2a',3a'). They did not react with Ta60b, which indicated that they did not express interleukin-2 receptor. Leukemia cells from two patients (nos. 1 and 5) reacted with OKT3, 9.6, and OKIal, but not with OKT4 or OKT8, which indicated that they retained the characteristics of peripheral T cells but did not express their specific subset marker.
Southern Blot Analysis for the HTLV-I Provirus Genome. The HTLV-I provirus was detectable in the ATL-1K cell line (9) as a 20-kb fragment when cellular DNA was digested with EcoRI, which does not cut the HTLV-I provirus sequence, and as 12.8-, 2.4-, 1.7-, and 1.3-kb fragments when DNA was digested with'Pst I, which cuts the provirus internally ( LTR (data not shown). However, there was no detectable proviral band in the digests of DNA from PBMCs, ascites or pericardial effusion cells of patients [1] [2] [3] [4] [5] . The absence of a proviral band was not due to extensive degradation of DNA, because when the same filter was washed and rehybridized with c-myc probe, the band of the c-myc gene could be clearly detected in leukemic cellular DNA from all five patients, as well as in control DNA from ATL-1K cells or from HL-60 cells, which showed the well-known amplification of c-myc (Fig. 3B) .
When the probe covering the whole gag region was used, DNA from ATL-1K cells showed the proviral band of 20 kb in an EcoRI digest and bands of 2.4 and 1.7 kb in a Pst I digest (Fig. 3C) . However, no band was detected in digests of DNA ofleukemia cells from any of the five patients. When the LTR probe was used, the proviral band of 20 kb was observed in an EcoRI digest of ATL-1K DNA (Fig. 3D ), but no band was seen in digests of leukemia-cell DNA from any of the five patients. Msp I, which is a restriction enzyme that cuts within the LTR sequence, was used to see whether the LTR sequence was integrated randomly. The expected bands of 0.1-0.2 kb were obtained with ATL-1K cells, but not with leukemia cells from any of the five patients. Fig. 3E demonstrates that one copy of the HTLV-I provirus sequence was found in ATL-1K cell DNA, but no significant band was detected (limit of detection, 0. (24) . However, their classification of T-cell malignancies was criticized as inaccurate (25) . Only three cases with pleomorphic convoluted lymphocytes were exactly ATL and were associated with HTLV-I. Other HTLV-I-unrelated cases were not ATL but more accurately diagnosed as T prolymphocytic leukemia or chronic T-lymphocytic leukemia, because leukemia cells of these cases did not show flower-cell morphology at all (25) .
Studies of surface markers showed that cases 2, 3, and 4 had the inducer/helper T-cell phenotype, whereas cases 1 and 5 expressed only the peripheral T-cell phenotype and their subset marker was not specified. The (26) , especially at the time of relapse or exacerbation.
These results indicate that there were no detectable differences between the clinicohematological, cytopathological, or immunophenotypic features of cases of HTLV-I-positive and HTLV-I-negative ATL. The presence of HTLV-ILnegative ATL suggests the existence of unknown cellular oncogenes closely related to the transformation of inducer/helper T cells. The absence of interleukin-2 receptor antigen in leukemia cells of patient 3 indicates that the interleukin-2 receptor may not be necessary for maintaining tumor growth in HTLV-I-negative ATL. We think that the role of HTLV-I in the etiology of ATL may be very similar to that of Epstein-Barr virus in Burkitt lymphoma. Namely, the causative agent of ATL may not always be HTLV-I, and hence, ATL may not always be defined as an HTLV-I-induced T-cell malignancy.
